both for its polenliallo threaten life acu tely a nd to cause permanent central nervous system (CNS) damage in survivors. While il is h eartening to observe th e stunning decline in cases of f-laemophilus i11]luenzae type b infection following the introdu ction of vaccination programs. cases of group B streptococcus. meningococcus. pneumococcus and other pathoge n s remain a ll too familiar.
The fundamental frustration for meningitis therapists is the lack of a co ns istent correlation b e tween prompt bacteriological cu re and a favourab le clinical outco me . With c urrently ava il a ble a ntibiotics . most cases h ave steril e cerebros pina l Ouid (CSF) with in 24 h of starling th era py . For c hildren with m eningitis. treatment with drugs such as ceflriaxon e results in b acteriological cure (sterile CSF) with in 24 h in approxi mately 93%. with the rema ining cases ·cured ' by 48 h (l). Equally impressive results were ach ieved with a mpicillin or chlora mph en icol in earlie r series. Desp ite prompt erad ication of bacteria the ris k of CNS sequelae remain s high.
In the past decade mu c h effort has go n e into improving understanding of th e pathophysiology of b ac terial meningitis. u s ing an ima l mode ls of infec tion . De ta iled information is now available (2) a boullhe specific components of bacteria lhallrigger in f1 ammalion in CSF: the inl1ammalion-enhancing effects of antib iotic-induced bacterial killing: a nd the med iators of CSF inl1 a mmalion and cerebral inju ry. Whi le th e c rude resu lts a re similar. the detailed mechanisms of injury vary re markably amo ng co mmon pathogens . Th e model s tudies suggest lhal control of meningeal inl1a mma lion during bacteria l eradica tion will red u ce CNS inju ry. but th ey a lso warn that effective control therapies may differ by pa thoge n (3.4) . In the case of mod els using H i11flue nzae type b organisms. co rticosteroid s a dministe red with the in itia l a ntibiotic therapy s ignifi cantly reduced CS F inl1a mmalion a nd brain edema (3) . prompting clinical trials to be undertaken in c hildren with men ingiti s .
The mod ern studies of co rti cos teroid adjunc tive therapy began in Dallas. using dexamethasone. Whi le these were ra ndomized. placebo contro ll ed. b lind ed
s tudies (5) . their design was explora tory in nature. ic, without s p ecified pt-imary outcome measures. The inili a ! repOI-t from Dallas. combining two studies involving diiTere nl cephalosporin antibiotics. involved more than two dozen comparisons . en compassing clin ical s igns . c h a nges in CSF composition. auditory tests a nd measures of persistent CNS injury . While the expected effec ts of treatment on fever and some CSF pa ra me ters were observed . th e only complication a meliora ted was sensorin eura l h earing loss . Subsequ ent studies of simila r design produced conf1i cting results. A noteworthy Swiss study (l) that emphasized a dministra tion of d exa m e th aso n e just before co mm e n ce m e nt of antibioti c therapy (th e strategy with greatest impact in a nima l models of men ingitis) demonstra ted ma rgin a l benefits. After 24 h . five of six indices of CSF inl1a mmalion h ad c hanged to similar eA.i.enls in both treatment groups . with on ly glucose concentrations improving faster with dexameth asone. Th e du ra tion of fever was not significantly shorter in dexame thasone-treated children. nor were the ra tes of persistent n eu rologica l or a udiological sequelae reduced significantly.
The stu dy by King et a l in this issu e of the Journal (pages 2 1 0-215) de monstra ted no improveme nt in the outcome of childhood men ingitis associa ted with use of dexamethasone, although th e n ecess ity to obtain informed consent delayed its use by a media n of 11 h after a ntibiotics . With well balanced treatm e nt groups h ea ring loss occurred in 10 a nd 11 % of the dexameth asone and placebo g roups. respectively . a nd neurological d efi cits occurred in 20 a nd 18%. respectively . One d exame thason e-treated child h ad a du odenal perforation . a poignant reminder that the use of this drug is not without ri s k.
A mullicenlre study in th e United Stales (6). in whic h ch il dren were trea ted with dexa m eth asone with in 4 h of starling an tibiotic therapy. a lso reported lack of efficacy. Th at study is noteworthy for its emphasis on h ea ring damage as a primary outcome measure. Most children h a d a udiome tric tests performed within 24 h of a dmission. by which lime most instances of senso rine ura l h earing impairm ent were a lready detectable. This is not a n ew insight because others (7.8) h ad previously demonstrated the early onset of hearing damage in meningitis cases and the potential for a proportion of cases to improve or recover. From a study design perspective, it would have been ideal (but admittedly impractical) in all of these studies to randomize separately patients who presented with hearing impairment. as the question is then whether dexamethasone treatment improves recovery. Failure to distribute patients randomly with early onset deafness may explain the inconsistent results of the recent studies, most of which were not large enough to ensure equal distribution of such patients by chance alone. In the American multicentre study (6) . dexamethasone treatment did not improve the outcome of early onset hearing impairment compared with placebo treatment.
In short, the promise of corticosteroid therapy surmized in studies of rabbits with meningitis has not been realized in afflicted children. 
